APO vs. NTB I find it truly bizarre that Acasti's market cap (as of 2:09pm today) is $89M. NTB's is $116M.
Acasti has like 10 employees and a wonder drug in the midst of clinical trials. NTB has like 100 employees, a bunch of marketable products, and distribution agreements all over the world.
Oh, and don't forget any uptick in APO flows to NTB by way of its 70% (or so) share ownership, and management fees and royalties.
When you consider there is close to $20M in cash in the mix, the market is saying there is essentially no value in NKO or Neurobiopharma.
Yet, in 2006, the market bid up NTB to $8 (when APO and CaPre were just a pipe dream).
Not sure on timing for the APO Nasdaq listing - only that management said it was short-term objective. I define "short-term" as less than a year.